Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
You may also be interested in...
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.